Clinical trials: Portal Vein Thrombosis
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Radiotherapy, Sorafenib
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma
This is a single-arm phase II clinical trial to investigate the efficacy and toxicity of concurrent sorafenib and intensity-modulated radiotherapy (IMRT) for advanced hepatocellular carcinoma with portal vein or hepatic vein…
- Trial name
- SIRAHCC (NCT03535259)
- Testing
- concurrent sorafenib and IMRT, followed sorafenib maintenance
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Liver Cirrhosis, Portal Vein
Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
The prevalence of portal vein thrombosis (PVT) in patients with liver cirrhosis is 5-20%. Current evidence regarding the effect of portal vein thrombosis on the prognosis of cirrhotic patients remains under debate.
- Conditions
- Liver Cirrhosis, Portal Vein, Venous Thrombosis, Varicose Veins
- Trial name
- NCT02335580
- Testing
- Somatostatin and its analogs, Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection
- Where
- China
- Volunteers
- 475 people
- Sponsor
- General Hospital of Shenyang Military Region
Cirrhosis, Splenectomy
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461545
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Carcinoma, Hepatocellular
Proteomic Analysis of Human Hepatocellular Carcinoma
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.
- Trial name
- NCT01177631
- Testing
- Operation
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Far Eastern Memorial Hospital
Hepatocellular Carcinoma
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus toripalimab versus hepatic arterial infusion chemotherapy of…
- Trial name
- NCT04135690
- Testing
- Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
For HCC patients with PVTT who the researchers believe can benefit from radiotherapy combined with tislelizumab and anlotinib, informed consent forms will be signed, and then they will receive the study treatment and be followed…
- Trial name
- NCT07363512
- Testing
- Radiotherapy combined with tislelizumab and anlotinib
- Volunteers
- 27 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC (NCT02309788)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Carcinoma, Hepatocellular
Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization
The primary goal of the study is to see if the PET/CT will be able to determine the precise location of the Y-90 particles within the liver and within the tumors.
- Trial name
- PET-Y90 (NCT02848638)
- Volunteers
- 35 people
- Sponsor
- University of Washington
Carcinoma. Hepatocellular
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
The presence of portal vein tumor thrombosis (PVTT)in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT01911000
- Testing
- RT and hyperthermia after TACE
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres.
- Trial name
- RESOLVE (NCT06166576)
- Testing
- Ablative radioembolization
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major…
- Trial name
- NCT02774187
- Testing
- Sorafenib, Hepatic arterial infusion chemotherapy, Folfox Protocol
- Where
- 5 sites in China
- Volunteers
- 247 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion
Recently, several studies reported promising outcomes of patients after external beam radiotherapy (EBRT) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis.
- Trial name
- NCT01850368
- Testing
- Stereotactic ablative radiotherapy
- Where
- 8 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Korea Cancer Center Hospital
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion chemotherapy) with HLX10 (PD-1 antibody) and HLX04…
- Trial name
- NCT04947826
- Testing
- HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Portal Vein Thrombosis, Liver Cirrhosis
Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
Portal vein thrombosis (PVT) is prevalent among patients with cirrhosis, and its prevalence rises with the severity of liver disease.
- Trial name
- NCT06818279
- Testing
- Dabigatran, Enoxaparin
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Neoplasm, Portal Vein Tumor Thrombosis
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
The standard treatment of advanced hepatocellular carcinoma (HCC) is sorafenib. Though the agent showed clear survival benefit in two randomized phase III trials, the benefit was modest and response rate was just a few percent.
- Conditions
- Liver Neoplasm, Portal Vein Tumor Thrombosis, Proton Therapy
- Trial name
- PTHP (NCT02571946)
- Testing
- Proton beam therapy
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Samsung Medical Center
Cirrhosis, Hypertension
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.
- Conditions
- Cirrhosis, Hypertension, Venous Thrombosis, Status; Splenectomy
- Trial name
- ESWA (NCT02238444)
- Testing
- Warfarin, Dipyridamole, Aspirin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yangzhou University